AzaSite®
azithromycin 1% · ophthalmic solution
Antibiotic
Approved uses
Bacterial conjunctivitis
1 drop in the affected eye(s) BID, 8 to 12 hours apart, x 2 days, then 1 drop QD x 5 days.
OFF-LABELNot in the FDA label for this product
Blepharitis
1 drop BID x 2 days, then 1 drop QD through day 28.
Open-label · n=26 · no control
Multicenter open-label study, 26 subjects with moderate to severe blepharitis treated without warm compresses or lid scrubs: meibomian gland plugging, eyelid margin redness, palpebral conjunctival redness and ocular discharge all fell from baseline at day 29 (P at or below 0.002) and remained improved 4 weeks after stopping (P at or below 0.006). Uncontrolled and unmasked; eyelid margin cultures fell for coagulase-negative staphylococci and Corynebacterium xerosis, while tear cytokine concentrations did not change.
Meibomian gland dysfunction (posterior blepharitis)
1 drop BID x 2 days, then 1 drop QD x 12 days, with warm compresses 5 to 10 minutes BID.
Randomized open-label · n=21
Randomized open-label trial, 21 patients (10 drug plus compresses, 11 compresses alone, 20 completed): greater improvement in meibomian gland plugging, secretion quality and eyelid redness than compresses alone at day 14; small, unmasked, single-site. A 2020 meta-analysis of 18 studies pooling oral and topical azithromycin for MGD (topical arms include both 1% and 1.5% formulations) reported symptom score improvement with SMD 1.54 (95% CI 1.15 to 1.92) and a 25% pooled adverse event rate for topical dosing.
Contraindications
Hypersensitivity to any component of this product.
1% solution, 2.5 mL in a 5 mL bottle, 25 mg of azithromycin per bottle
Macrolide antibiotic; binds the 50S ribosomal subunit of susceptible organisms and interferes with microbial protein synthesis. Systemic exposure after ocular dosing is estimated to fall below quantifiable limits (10 ng/mL or less) at steady state, assuming 100% systemic availability.
Warnings & Precautions
- Topical ophthalmic use only: Not for injection; should not be administered systemically, injected subconjunctivally, or introduced directly into the anterior chamber.
- Anaphylaxis and hypersensitivity: Angioedema, anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported rarely in patients receiving systemically administered azithromycin; although rare, fatalities have been reported; consider the potential for anaphylaxis or other hypersensitivity reactions based on known hypersensitivity to azithromycin when administered systemically.
- Resistant organism overgrowth: Prolonged use may cause overgrowth of non-susceptible organisms including fungi; discontinue and start alternative therapy if super-infection occurs; whenever clinical judgment dictates, examine with magnification, such as slit-lamp biomicroscopy, and where appropriate, fluorescein staining.
- Contamination of the applicator tip: Avoid contaminating the applicator tip by not allowing it to touch the eye, fingers or other sources.
- Avoidance of contact lenses: Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.
Common Side Effects
In 698 patients, the most frequently reported ocular adverse reaction was eye irritation, in approximately 1 to 2% of patients. Other adverse reactions were reported in less than 1% of patients and included ocular reactions (blurred vision, burning, stinging and irritation upon instillation, contact dermatitis, corneal erosion, dry eye, eye pain, itching, ocular discharge, punctate keratitis, visual acuity reduction) and non-ocular reactions (dysgeusia, facial swelling, hives, nasal congestion, periocular swelling, rash, sinusitis, urticaria).
Pregnancy: Published literature and postmarketing experience over several decades with azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes; developmental toxicity studies in rats, mice, and rabbits showed no drug-induced fetal malformations at doses up to 200 mg/kg/day.
Lactation: Azithromycin is present in human milk, and non-serious adverse reactions have been reported in breastfed infants after maternal oral azithromycin; there are no available data on effects on milk production; consider the benefits of breastfeeding along with the mother's clinical need for AzaSite and any potential adverse effects on the breastfed infant.
Safety and effectiveness in pediatric patients have been established; efficacy in pediatric bacterial conjunctivitis was demonstrated in controlled clinical trials.